- Iron Supplements
- Erythropoietin Or Erythrocyte-Stimulating Agents
- Vitamin B12 Supplements
- Folic Acid Supplements
Anemia In The Elderly Market was valued at USD 2,846.9 million in 2023 and is poised to grow at a CAGR of 9.1% over 2024-2030. Anemia is a condition characterized by a deficiency of red blood cells or hemoglobin in the blood, leading to reduced oxygen-carrying capacity and potential health complications. Anemia is more prevalent in the elderly due to various factors such as nutritional deficiencies, chronic diseases, and age-related changes in the bone marrow. It can be a significant health concern for this population, as it can exacerbate existing health conditions, lead to fatigue, weakness, and impaired cognitive function, and reduce overall quality of life.
The Anemia in the Elderly Market is driven by the growing elderly population globally and increasing awareness of the importance of addressing anemia in older adults to improve their overall health and well-being. As with any healthcare market, research and development efforts continue to advance diagnostics, treatments, and interventions to better address the specific needs of this vulnerable population. The prevalence of anemia in the elderly population can vary significantly in various regions globally. For instance, according to report findings, Anemia’s prevalence rate in the elderly population is estimated to be 10% in the United States and Europe. This estimation increases further with age greater than 80 years and among hospitalized patients or residents at nursing homes. Moreover, Pharmaceutical companies develop and market drugs targeting anemia in elderly patients, and medical devices for blood testing and monitoring are also part of the market.
Anemia In Elderly Market Key Developments:
- In August 2018, Memorial Healthcare System Hollywood, Florida, United States under the sponsorship of AMAG Pharmaceuticals, Inc. conducting a phase 3 study to evaluate the safety, efficacy, and pharmacokinetics of Ferumoxytol for the treatment of iron deficiency anemia in pediatric patients with chronic kidney diseases.
Anemia In Elderly Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
9.1%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Anemia In Elderly Market Dynamics
The Anemia in Elderly Market is poised for significant growth due to several key drivers and opportunities. Firstly, the global aging population is increasing, leading to a higher prevalence of anemia in elderly individuals. This demographic shift is expected to fuel the demand for diagnostic tests, pharmaceuticals, and nutritional supplements to address the condition effectively. Additionally, rising awareness about anemia's impact on the elderly's quality of life and overall health is driving increased healthcare spending and research in this area. Furthermore, advancements in medical technology and treatment options present opportunities for innovative therapies and interventions tailored to the unique needs of elderly patients. With a focus on improving patient outcomes and enhancing geriatric care, the market is likely to witness significant investments and collaborations between healthcare providers and pharmaceutical companies.
North-America Got Significant Share
Anemia In Elderly Market Regional Analysis
In the USA, the Anemia in Elderly Market faces a mix of challenges and growth factors. On the one hand, the aging population in the country is steadily increasing, leading to a higher prevalence of anemia among the elderly. According to the U.S. Census Bureau, the number of people aged 65 and older is projected to grow from 56 million in 2020 to 94.7 million by 2060. Additionally, According to report findings in 2018, the prevalent population of Anemia in the Elderly (65+) in the United States was found to be 5,557,706. This demographic shift presents a significant growth opportunity for the market as it drives the demand for diagnostic tests, treatments, and interventions. However, the market also encounters challenges. One major restraint is the underdiagnosis of anemia in the elderly, which can result from symptoms being mistakenly attributed to aging or other comorbidities.
This calls for increased awareness among healthcare professionals and the general public about the importance of early detection and management of anemia in this population. Additionally, cost concerns and reimbursement issues for certain treatments may hinder the accessibility of advanced therapies for some elderly patients. To overcome these challenges and leverage growth opportunities, research and development efforts are ongoing to develop more accurate diagnostic tools and innovative treatments. Moreover, collaborations between healthcare providers, pharmaceutical companies, and government agencies are crucial in devising effective strategies to tackle anemia in the elderly population effectively.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The anemia in elderly market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Anemia In Elderly Market Segmentation
By Treatment
By Product Type
- Tablets
- Injectable
By Dosage Forms
- Solid
- Liquid
By Route of Administration
- Oral
- Parenteral
By Age
- Pediatrics
- Adults
- Geriatrics
By End User
- Hospital pharmacy
- Online Pharmacy
- Retail pharmacy
Frequently Asked Questions
The anemia in elderly market was valued at USD 2,846.9 million in 2022 and is expected to grow at 9.1% CAGR over the forecast period 2023 – 2029.
Key opportunities for the anemia in elderly market include the growing aging population, increased awareness about anemia's impact on elderly health, and advancements in medical technology to develop innovative therapies tailored to elderly patients.
The key trends in the anemia in the elderly market include the rising prevalence of anemia among the aging population, advancements in personalized therapies, and a focus on integrated healthcare approaches for improved diagnosis and management.
Vifor Pharma, Sandoz International GmbH, Contract Pharmacal Corp., Akebia Therapeutics Inc., Amgen Inc., Rockwell Medical Inc., Covis Pharma GmbH, and Hoffmann-La Roche Ltd. are prominent companies operating in the field of Anemia In Elderly Market.
| 1.Executive Summary |
| 2.Global Anemia In Elderly Market Introduction |
| 2.1.Global Anemia In Elderly Market - Taxonomy |
| 2.2.Global Anemia In Elderly Market - Definitions |
| 2.2.1.Treatment |
| 2.2.2.Product Type |
| 2.2.3.Dosage Forms |
| 2.2.4.Route of Administration |
| 2.2.5.Region |
| 3.Global Anemia In Elderly Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Anemia In Elderly Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Anemia In Elderly Market By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Iron Supplements |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Erythropoietin Or Erythrocyte-Stimulating Agents |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Vitamin B12 Supplements |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Folic Acid Supplements |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Anemia In Elderly Market By Product Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Tablets |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Injectable |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Anemia In Elderly Market By Dosage Forms, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Solid |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Liquid |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8.Global Anemia In Elderly Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Oral |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Parenteral |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 9.Global Anemia In Elderly Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Anemia In Elderly Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Iron Supplements |
| 10.1.2.Erythropoietin Or Erythrocyte-Stimulating Agents |
| 10.1.3.Vitamin B12 Supplements |
| 10.1.4.Folic Acid Supplements |
| 10.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Tablets |
| 10.2.2. Injectable |
| 10.3. Dosage Forms Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Solid |
| 10.3.2.Liquid |
| 10.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Oral |
| 10.4.2.Parenteral |
| 10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Anemia In Elderly Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Iron Supplements |
| 11.1.2.Erythropoietin Or Erythrocyte-Stimulating Agents |
| 11.1.3.Vitamin B12 Supplements |
| 11.1.4.Folic Acid Supplements |
| 11.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Tablets |
| 11.2.2. Injectable |
| 11.3. Dosage Forms Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Solid |
| 11.3.2.Liquid |
| 11.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Oral |
| 11.4.2.Parenteral |
| 11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 12.Asia Pacific (APAC) Anemia In Elderly Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Iron Supplements |
| 12.1.2.Erythropoietin Or Erythrocyte-Stimulating Agents |
| 12.1.3.Vitamin B12 Supplements |
| 12.1.4.Folic Acid Supplements |
| 12.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Tablets |
| 12.2.2. Injectable |
| 12.3. Dosage Forms Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Solid |
| 12.3.2.Liquid |
| 12.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Oral |
| 12.4.2.Parenteral |
| 12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Anemia In Elderly Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Iron Supplements |
| 13.1.2.Erythropoietin Or Erythrocyte-Stimulating Agents |
| 13.1.3.Vitamin B12 Supplements |
| 13.1.4.Folic Acid Supplements |
| 13.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Tablets |
| 13.2.2. Injectable |
| 13.3. Dosage Forms Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Solid |
| 13.3.2.Liquid |
| 13.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Oral |
| 13.4.2.Parenteral |
| 13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Anemia In Elderly Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 14.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Iron Supplements |
| 14.1.2.Erythropoietin Or Erythrocyte-Stimulating Agents |
| 14.1.3.Vitamin B12 Supplements |
| 14.1.4.Folic Acid Supplements |
| 14.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1. Tablets |
| 14.2.2. Injectable |
| 14.3. Dosage Forms Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Solid |
| 14.3.2.Liquid |
| 14.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Oral |
| 14.4.2.Parenteral |
| 14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1. Vifor Pharma |
| 15.2.2.Sandoz International GmbH |
| 15.2.3.Contract Pharmacal Corp. |
| 15.2.4.Akebia Therapeutics Inc. |
| 15.2.5.Amgen Inc. |
| 15.2.6.Rockwell Medical Inc. |
| 15.2.7.Covis Pharma GmbH |
| 15.2.8.Hoffmann-La Roche Ltd |
| 15.2.9.Pfizer Inc. |
| 15.2.10.Novartis AG |
| 15.2.11.Johnson & Johnson |
| 15.2.12.Teva Pharmaceutical Industries Ltd. |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
- Vifor Pharma
- Sandoz International GmbH
- Contract Pharmacal Corp.
- Akebia Therapeutics Inc.
- Amgen Inc.
- Rockwell Medical Inc.
- Covis Pharma GmbH
- Hoffmann-La Roche Ltd
- Pfizer Inc.
- Novartis AG
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.